Ivosidenib and Combination Chemotherapy
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 25 patients (estimated)
- Sponsors
- Northwestern University
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Isocitrate Dehydrogenase 1 (IDH1) Inhibitor, MIDH2 Inhibitor, White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1756
- NCT Identifier
- NCT04250051
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.